[Experience and results of acute lymphoblastic leukaemia treatment in children between 1989-2005 in Navarre].
BACKGROUND
The determination of prognostic factors in acute lymphoblastic leukaemia (ALL) is increasingly important in establishing a correct treatment. We analyse the overall survival (OS), event free survival (EFS) and prognostic factors in our 16 years experience of treating acute lymphoblastic leukaemia.


METHODS
We performed univariate and multivariate analyses of the prognostic factors we considered most significant in our serie of patients.


RESULTS
From January 1989 to December 2005, 50 cases of ALL were reported in 58 patients with LA. We analysed a subgroup of 41 patients with LLA as they were included in standard protocols. In this group the EFS was 78% and OS 87.8%. Inmunophenotype is a predictor of prognosis when we compare Common with Others, with a HR of 13.82 (CI95%: 1.019-166.008) p<0.05; Protocol of Treatment of the Paediatric Haematology Oncology Society (SHOP) (94-99/89) with HR of 0.065 (CI95%: 0.005-0.008) p<0.02; and Age (>120 months/12-120 months) with a HR of 13.82 (CI95%: 0.58-329.48) p=0.1.


CONCLUSIONS
The OS in our series is similar to that reported in the literature. Inmunophenotype and protocols of treatment are the most significant prognostic factors.
Molina
J
J
Oncohematología Pediátrica, Servicio de Pediatría, Hospital Virgen del Camino, Pamplona, Spain. jmolinag@cfnavarra.es
Molins
T
T
Gil
F J
FJ
Sagaseta de Ilurdoz
M
M
Ruipérez
E
E
Guembero
E
E
Sala
F
F
Valiente
A
A
Labaca
M A
MA
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D020732:Cytogenetic Analysis; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012307:Risk Factors; D013030:Spain; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome